Abstract 5084: Potent and isoform-selective ATAD2 bromodomain inhibitor with unprecedented chemical structure and mode of action

• Published in: Cancer research (Chicago, Ill.) Vol. 77; no. 13_Supplement; p. 5084
• Main Authors: Fernández-Montalván, Amaury E., Berger, Markus, Kuropka, Benno, Koo, Seong Joo, Badock, Volker, Weiske, Joerg, Holton, Simon J., Chaikuad, Apirat, Díaz-Sáez, Laura, Bennett, James, Federov, Oleg, Huber, Kilian, Centrella, Paolo, Clark, Matthew A., Dumelin, Christoph E., Sigel, Eric A., Soutter, Holly S., Troast, Dawn M., Zhang, Ying, Cuozzo, John W., Keefe, Anthony D., Roche, Didier, Rodeschini, Vincent, Hübner, Jan, Weinmann, Hilmar, Hartung, Ingo V., Gorjanacz, Matyas
• Format: Journal Article
• Language: English
• Published: 01.07.2017

Abstract ATAD2 (ATPase family AAA-domain containing protein 2, also called ANCCA) is an epigenetic regulator that binds to chromatin through its bromodomain (BD), a motif specialized for acetyl-lysine recognition. ATAD2 directly associates with multiple transcription factors such as ERα, AR, E2F, an...